Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.
Clinical trial NCT06961331 · COMPLETED
Trial details
- NCT number
- NCT06961331
- Sponsor
- Pfizer
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2025-05-07
- Primary completion
- 2025-09-25
- Enrollment
- 86
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.